Mount Sinai Health System is an academic health system and biomedical research organization based in New York City. It encompasses a network of hospitals and outpatient centers, anchored by The Mount Sinai Hospital, and is closely integrated with the Icahn School of Medicine at Mount Sinai. The system provides comprehensive patient care across a broad range of specialties while training healthcare professionals and advancing medical science.
Mount Sinai conducts extensive clinical and translational research, including investigator-led and industry-sponsored clinical trials in areas such as neurology, neurosurgery, oncology, cardiology, and population health. Its research institutes and laboratories collaborate with partners in biotechnology, pharmaceuticals, and medical technology to develop and evaluate new diagnostics, therapies, and care models.
Also known as Mount Sinai Hospital.
Randomized MEMBRANE trial found adding middle meningeal artery embolization with TRUFILL n‑BCA to standard care lowered chronic subdural hematoma recurrence and re‑intervention.
Neutral trial. 30‑min Impella improved pre‑PCI TIMI flow. Age 61+ trended smaller infarcts. More bleeding/vascular events but no higher 12‑month mortality. Elevated lactate predicted larger infarcts.
FDA approves TRUFILL n-BCA for MMA embolization in chronic subdural hematoma, offering a minimally invasive alternative to surgery with proven safety and effectiveness.
